Research Analysts’ Recent Ratings Updates for Tarsus Pharmaceuticals (TARS)

Tarsus Pharmaceuticals (NASDAQ: TARS) has recently received a number of price target changes and ratings updates:

• 3/6/2025 – Tarsus Pharmaceuticals had its price target raised by analysts at Jefferies Financial Group Inc. from $54.00 to $58.00. They now have a “buy” rating on the stock.
• 2/26/2025 – Tarsus Pharmaceuticals had its price target lowered by analysts at Barclays PLC from $62.00 to $60.00. They now have an “overweight” rating on the stock.
• 2/26/2025 – Tarsus Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $73.00 price target on the stock.
• 2/24/2025 – Tarsus Pharmaceuticals had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $78.00 price target on the stock, up previously from $75.00.
• 2/10/2025 – Tarsus Pharmaceuticals had its “buy” rating reaffirmed by analysts at Guggenheim.
• 1/27/2025 – Tarsus Pharmaceuticals had its price target raised by analysts at Barclays PLC from $60.00 to $62.00. They now have an “overweight” rating on the stock.
• 1/22/2025 – Tarsus Pharmaceuticals had its price target raised by analysts at Oppenheimer Holdings Inc. from $65.00 to $72.00. They now have an “outperform” rating on the stock.

Tarsus Pharmaceuticals Price Performance

TARS stock traded up $0.48 during midday trading on Friday, reaching $46.95. The company had a trading volume of 133,117 shares, compared to its average volume of 639,484. Tarsus Pharmaceuticals, Inc. has a 1-year low of $20.08 and a 1-year high of $57.28. The stock has a 50 day moving average price of $49.26 and a 200-day moving average price of $44.32. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of -12.32 and a beta of 1.05.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The firm had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. Equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in TARS. Paradigm Biocapital Advisors LP increased its stake in shares of Tarsus Pharmaceuticals by 3.7% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 2,531,896 shares of the company’s stock valued at $140,191,000 after purchasing an additional 91,451 shares during the last quarter. Jennison Associates LLC grew its position in Tarsus Pharmaceuticals by 14.8% in the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company’s stock valued at $138,432,000 after acquiring an additional 321,552 shares during the last quarter. Vanguard Group Inc. raised its stake in Tarsus Pharmaceuticals by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 2,115,162 shares of the company’s stock worth $117,117,000 after acquiring an additional 17,839 shares in the last quarter. Toronto Dominion Bank bought a new position in shares of Tarsus Pharmaceuticals in the fourth quarter worth about $105,714,000. Finally, Lord Abbett & CO. LLC increased its position in Tarsus Pharmaceuticals by 115.2% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company’s stock worth $70,873,000 after purchasing an additional 685,111 shares in the last quarter. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.